Modifier genes for hypertrophic cardiomyopathy.

PubWeight™: 1.47‹?› | Rank: Top 5%

🔗 View Article (PMC 2775140)

Published in Curr Opin Cardiol on May 01, 2002

Authors

A J Marian1

Author Affiliations

1: Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. amarian@bcm.tmc.edu

Articles citing this

Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells. Cardiovasc Res (2014) 2.25

Genetic determinants of cardiac hypertrophy. Curr Opin Cardiol (2008) 1.35

Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart (2005) 1.24

Cardiac hypertrophy and sudden death in mice with a genetically clamped renin transgene. Proc Natl Acad Sci U S A (2004) 1.21

Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest (2010) 1.17

Allele and species dependent contractile defects by restrictive and hypertrophic cardiomyopathy-linked troponin I mutants. J Mol Cell Cardiol (2008) 1.14

Contemporary treatment of hypertrophic cardiomyopathy. Tex Heart Inst J (2009) 1.12

Nature's genetic gradients and the clinical phenotype. Circ Cardiovasc Genet (2009) 1.04

Molecular genetics and pathogenesis of cardiomyopathy. J Hum Genet (2015) 1.02

Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes. J Mol Cell Cardiol (2010) 0.96

Combinatorial effects of double cardiomyopathy mutant alleles in rodent myocytes: a predictive cellular model of myofilament dysregulation in disease. PLoS One (2010) 0.86

Hypertrophic cardiomyopathy family with double-heterozygous mutations; does disease severity suggest doubleheterozygosity? Neth Heart J (2009) 0.86

Faster cross-bridge detachment and increased tension cost in human hypertrophic cardiomyopathy with the R403Q MYH7 mutation. J Physiol (2014) 0.85

Evidence for nuclear modifier gene in mitochondrial cardiomyopathy. J Mol Cell Cardiol (2009) 0.85

Is 8860 variation a rare polymorphism or associated as a secondary effect in HCM disease? Arch Med Sci (2011) 0.84

Familial hypertrophic cardiomyopathy associated with cardiac beta-myosin heavy chain and troponin I mutations. Pediatr Cardiol (2008) 0.84

On predictors of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol (2003) 0.83

Genetic variation in angiotensin-converting enzyme 2 gene is associated with extent of left ventricular hypertrophy in hypertrophic cardiomyopathy. Hum Genet (2008) 0.83

Hypertrophic cardiomyopathy: a heart in need of an energy bar? Front Physiol (2014) 0.82

Can an energy-deficient heart grow bigger and stronger? J Am Coll Cardiol (2003) 0.80

A Review of the Giant Protein Titin in Clinical Molecular Diagnostics of Cardiomyopathies. Front Cardiovasc Med (2016) 0.79

Identification and functional analysis of a new putative caveolin-3 variant found in a patient with sudden unexplained death. J Biomed Sci (2014) 0.77

A Murine Hypertrophic Cardiomyopathy Model: The DBA/2J Strain. PLoS One (2015) 0.76

MYBPH acts as modifier of cardiac hypertrophy in hypertrophic cardiomyopathy (HCM) patients. Hum Genet (2016) 0.75

Hyaluronidase 2 Deficiency Causes Increased Mesenchymal Cells, Congenital Heart Defects, and Heart Failure. Circ Cardiovasc Genet (2017) 0.75

Serum Biomarkers of Myocardial Remodeling and Coronary Dysfunction in Early Stages of Hypertrophic Cardiomyopathy in the Young. Pediatr Cardiol (2017) 0.75

Benazepril and subclinical feline hypertrophic cardiomyopathy: a prospective, blinded, controlled study. Can Vet J (2006) 0.75

Recent Advances in the Molecular Genetics of Familial Hypertrophic Cardiomyopathy in South Asian Descendants. Front Physiol (2016) 0.75

Image-guided cardiovascular functional genomics: finding the needle in the haystack. J Nucl Cardiol (2007) 0.75

Next-generation sequencing identifies pathogenic and modifier mutations in a consanguineous Chinese family with hypertrophic cardiomyopathy. Medicine (Baltimore) (2017) 0.75

Articles cited by this

A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature (2001) 42.18

Genetic dissection of complex traits. Science (1994) 29.54

High-resolution haplotype structure in the human genome. Nat Genet (2001) 20.51

Searching for genetic determinants in the new millennium. Nature (2000) 17.50

Linkage disequilibrium in the human genome. Nature (2001) 17.24

An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest (1990) 10.35

Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA (1996) 7.03

Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation (1995) 6.55

A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell (1990) 5.77

Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell (1994) 4.47

Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med (2001) 4.46

Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med (1995) 4.37

Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med (1998) 4.29

Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med (1992) 4.20

Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med (2000) 3.99

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 3.96

Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation (2001) 3.21

Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet (1996) 3.02

Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.97

Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu----Val mutation and a 403Arg----Gln mutation. Circulation (1992) 2.67

Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet (2000) 2.57

Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet (2001) 2.56

Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.52

Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet (1993) 2.38

Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol (2000) 2.33

Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Circ Res (1997) 2.25

Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation (2001) 2.23

Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet (1997) 2.20

Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation (1998) 2.04

Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med (1986) 2.00

Cardiac disease in myotonic dystrophy. Cardiovasc Res (1997) 1.98

Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol (2001) 1.97

Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. Am J Hum Genet (2001) 1.91

Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the beta-myosin heavy chain genes. Eur Heart J (1998) 1.79

Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol (2001) 1.74

Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest (1994) 1.69

Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation (1981) 1.66

Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest (1999) 1.64

Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation (2001) 1.64

Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem Biophys Res Commun (1999) 1.48

Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy. Circulation (2000) 1.39

Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol (2000) 1.35

Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. J Clin Invest (1992) 1.30

Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. J Mol Med (Berl) (1998) 1.27

Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation (1995) 1.26

Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J Am Coll Cardiol (2001) 1.24

Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis. Cardiovasc Res (1997) 1.23

Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Circulation (1995) 1.21

Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. Circulation (1996) 1.18

First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Hum Mutat (2001) 1.17

Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. J Investig Med (1997) 1.15

AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension (1998) 1.15

Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and identification of a hot spot for mutations in the beta-myosin heavy chain gene. J Clin Invest (1993) 1.13

Mitochondrial disorders: clinical and genetic features. Annu Rev Med (1999) 1.10

Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis. Circulation (2001) 1.09

Sudden cardiac death in hypertrophic cardiomyopathy. Variability in phenotypic expression of beta-myosin heavy chain mutations. Eur Heart J (1995) 1.08

Prognostic significance of beta-myosin heavy chain mutations is reflective of their hypertrophic expressivity in patients with hypertrophic cardiomyopathy. J Investig Med (1997) 1.06

Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene. Circulation (2000) 1.05

The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol (1997) 1.05

Detection of a new mutation in the beta-myosin heavy chain gene in an individual with hypertrophic cardiomyopathy. J Clin Invest (1992) 1.03

Molecular genetics and pathogenesis of hypertrophic cardiomyopathy. Minerva Med (2001) 1.00

Clinical features of hypertrophic cardiomyopathy caused by mutation of a "hot spot" in the alpha-tropomyosin gene. J Am Coll Cardiol (1997) 0.99

Heritability of cardiac size: an echocardiographic and electrocardiographic study of monozygotic and dizygotic twins. Circulation (1985) 0.98

Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol (2000) 0.97

Independent origin of identical beta cardiac myosin heavy-chain mutations in hypertrophic cardiomyopathy. Am J Hum Genet (1993) 0.97

Myotonic dystrophy: molecular windows on a complex etiology. Nucleic Acids Res (1998) 0.95

Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation (1993) 0.95

Friedreich's ataxia and frataxin: molecular genetics, evolution and pathogenesis (Review). Int J Mol Med (2001) 0.94

Angiotensin-converting enzyme and heart chymase gene polymorphisms in hypertrophic cardiomyopathy. Am J Cardiol (1996) 0.94

A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated beta-myosin heavy chain genes. Hum Genet (1998) 0.93

Angiotensinogen gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J (1997) 0.93

Independent genetic susceptibility to cardiac hypertrophy in inherited hypertension. Hypertension (1998) 0.92

What is Kearns-Sayre syndrome after all? Arch Neurol (2001) 0.90

Familial predisposition of left ventricular hypertrophy. J Am Coll Cardiol (1999) 0.90

Lack of association of polymorphisms of the angiotensin converting enzyme and angiotensinogen genes with nonfamilial hypertrophic or dilated cardiomyopathy. Am J Hypertens (1997) 0.89

Role of the renin-angiotensin system in cardiac hypertrophy. Am J Cardiol (1999) 0.88

The GAA repeat expansion in intron 1 of the frataxin gene is related to the severity of cardiac manifestation in patients with Friedreich's ataxia. J Mol Med (Berl) (2001) 0.86

Genetic determination of cardiac mass in normotensive rats: results from an F344xWKY cross. Hypertension (1999) 0.85

Genotype-phenotype analysis in four families with mutations in beta-myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy. Hum Mutat (1998) 0.85

On genetic and phenotypic variability of hypertrophic cardiomyopathy: nature versus nurture. J Am Coll Cardiol (2001) 0.84

Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J (1995) 0.83

Screening the human bradykinin B2 receptor gene in patients with cardiovascular diseases: identification of a functional mutation in the promoter and a new coding variant (T21M). Am J Med Genet (1998) 0.79

A previously undescribed de novo insertion-deletion mutation in the beta myosin heavy chain gene in a kindred with familial hypertrophic cardiomyopathy. Heart (1996) 0.79

Canaries in the coal mine: mitochondrial DNA and vascular injury from reactive oxygen species. Circ Res (2000) 0.79

Association of a G994 --> T (Val279 --> Phe) polymorphism of the plasma platelet-activating factor acetylhydrolase gene with myocardial damage in Japanese patients with nonfamilial hypertrophic cardiomyopathy. J Hum Genet (2001) 0.78

On genetics, inflammation, and abdominal aortic aneurysm: can single nucleotide polymorphisms predict the outcome? Circulation (2001) 0.76